Whitepaper
26 Oct 2021

Monoclonal Antibody Manufacturing for Biopharma - Should I build or outsource

PDF 1.5 MB

A company’s strategy is crucial for determining future success, and therefore, it needs to constantly change in line with market dynamics. Although building in-house offer the advantage of direct control, the time, labor, and spend required to implement this often makes it the inefficient choice. From this whitepaper, you will learn about the parameters to consider when selecting a CDMO.

Content provided by our supplier

Samsung Biologics Co., Ltd.

  • KR
  • 2018
    On CPhI since
  • 1000 - 4999
    Employees

Other Content from Samsung Biologics Co., Ltd.